Fast Market Research

Recent Study: Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017

Fast Market Research announces the availability of the new Global Markets Direct report, "Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017", on their comprehensive research portal

 

Boston, MA -- (SBWIRE) -- 06/13/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape.

Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as the blood vessels that supply the muscles. IBM symptoms include progressive weakness of the muscles of the wrists and fingers, the muscles of the front of the thigh, and the muscles that lift the front of the foot.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get More Details on this Report and a Full Table of Contents at Inclusion Body Myositis (IBM) - Pipeline Review, H1 2017

The Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Inclusion Body Myositis (IBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Inclusion Body Myositis (IBM) (Musculoskeletal Disorders). -

The pipeline guide reviews pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. -

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. -

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. -

The pipeline guide reviews key companies involved in Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. -

The pipeline guide evaluates Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. -

The pipeline guide encapsulates all the dormant and discontinued pipeline projects. -

The pipeline guide reviews latest news related to pipeline therapeutics for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders)

Reasons to Get this Report

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. -

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. -

Find and recognize significant and varied types of therapeutics under development for Inclusion Body Myositis (IBM) (Musculoskeletal Disorders). -

Classify potential new clients or partners in the target demographic. -

Develop tactical initiatives by understanding the focus areas of leading companies. -

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. -

Companies Mentioned in this Report: Acceleron Pharma Inc, KPI Therapeutics Inc, Milo Biotechnology LLC, Nobelpharma Co Ltd, Orphazyme ApS, Ultragenyx Pharmaceutical Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Inclusion Body Myositis (IBM) - Pipeline Review, H2 2016
-Sepsis - Pipeline Review, H1 2017
-Diabetic Gastroparesis - Pipeline Review, H1 2017
-Radiation Toxicity - Pipeline Review, H1 2017
-Cystic Fibrosis - Pipeline Review, H1 2017